10-Q: SELLAS Life Sciences Reports Strong Clinical Progress, Bolstered Cash

SELLAS Life Sciences Group, Inc. reported a reduced net loss and significantly increased cash reserves, driven by successful capital raises and positive clinical trial advancements for its SLS009 candidate.

Summary

• Net loss for the nine months ended September 30, 2025, decreased to $19.2 million from $24.1 million in the prior year period.
• Cash and cash equivalents increased to $44.3 million as of September 30, 2025, from $13.9 million at December 31, 2024.
• The company secured approximately $22.0 million in net proceeds from a September 2025 warrant inducement and an additional $29.1 million from an October 2025 warrant inducement (subsequent event).
• SLS009's Phase 2 trial in relapsed/refractory AML met all primary endpoints, achieving an overall response rate (ORR) of 33% across all cohorts, with 40% for the 30 mg BIW dose level, and 44% in AML MR patients, exceeding the pre-specified 20% threshold.
• Median overall survival (mOS) for SLS009 in AML MR patients reached 8.9 months and 8.8 months in r/r to venetoclax-based regimens at a 30 mg BIW dose level, significantly surpassing the historical benchmark of approximately 2.4 months.
• The FDA recommended advancing SLS009 into a first-line therapy study for newly diagnosed AML patients, with enrollment expected by Q1 2026.
• The REGAL study (Phase 3 for GPS in AML) continues without modification following positive recommendations from the Independent Data Monitoring Committee (IDMC) in January and August 2025, with final analysis anticipated once 80 events (deaths) are reached this year.
• Research and development expenses decreased by $3.4 million to $11.3 million for the nine months ended September 30, 2025, primarily due to the completion of REGAL study enrollment.
• General and administrative expenses decreased by $1.2 million to $8.7 million for the nine months ended September 30, 2025, mainly due to a one-time severance charge in the prior period.

Sentiment

Score: 8

Explanation: The company demonstrated strong clinical progress with SLS009, exceeding historical benchmarks and receiving positive FDA guidance, which are significant milestones. Substantial capital raises have significantly improved liquidity, providing a runway for operations. While the company still incurs losses and faces a legal dispute, the clinical advancements and strengthened financial position present a very positive outlook for its pipeline.

Positives

• Net loss significantly decreased by $4.9 million for the nine months ended September 30, 2025, compared to the same period in 2024.
• Cash and cash equivalents increased by over $30 million to $44.3 million, substantially strengthening the balance sheet.
• Successful capital raises through warrant inducements and offerings generated over $80 million in net proceeds (including subsequent events), providing funding for at least the next twelve months.
• SLS009 Phase 2 trial in r/r AML met all primary endpoints, demonstrating strong efficacy with an ORR of 33% (exceeding 20% threshold) and mOS of 8.9 months (surpassing historical 2.4 months benchmark).
• FDA guidance to advance SLS009 into a first-line AML therapy study is a significant regulatory and clinical validation.
• SLS009 showed high efficacy in AML patients with ASXL1 mutations (50% ORR) and M4/M5 patients (50% ORR).
• Preclinical studies identified ASXL1 mutation as a key predictor of SLS009 response in solid cancers, expanding potential indications.
• SLS009 demonstrated significant efficacy in pediatric ALL patient-derived xenograft models, tripling median survival and showing complete responses in some models.
• GPS REGAL study (Phase 3 AML) received positive recommendations from the IDMC to continue without modifications, indicating ongoing promise.
• Multiple Orphan Drug and Fast Track designations for both GPS and SLS009 from FDA and EMA highlight the unmet medical need and potential for expedited review.

Negatives

• The company continues to incur recurring losses and negative cash flows from operations, with an accumulated deficit of $267.3 million as of September 30, 2025.
• A binding arbitration proceeding against 3D Medicines is ongoing regarding milestone payments and failure to use commercially reasonable best efforts to develop GPS in the 3DMed Territory, creating uncertainty around potential future licensing revenue.
• The company will need additional funding beyond the next twelve months to support planned operating activities through profitability, with no guarantee of obtaining such funding on favorable terms, which could be dilutive to existing stockholders.

Risks

• Risks associated with preclinical or clinical development and trials, including unexpected results or delays.
• Changes in assumptions underlying expectations regarding future business or business model.
• Ability to develop, manufacture, and commercialize product candidates.
• General economic, financial, legal, political, and business conditions and changes in domestic and foreign markets.
• Changes in applicable laws or regulations.
• Impact of natural disasters, including climate change, and health epidemics on the business.
• Size and growth potential of the markets for products, and the ability to serve those markets.
• Market acceptance of planned products.
• Ability to raise capital.
• Possibility of being adversely affected by other economic, business, and/or competitive factors.
• Uncertainty regarding the outcome of the binding arbitration proceeding against 3D Medicines, including the timing and receipt of milestone payments and other damages.

Future Outlook

The company expects its current cash and cash equivalents, combined with recent capital raises, to fund planned operations for at least the next twelve months. Research and development expenses are anticipated to increase as the company prepares for a potential Biologics License Application (BLA) filing for GPS and initiates a first-line AML trial for SLS009. The final analysis for the REGAL study is expected once 80 events (deaths) are reached this year. Enrollment for the new SLS009 first-line AML trial is expected to begin by the first quarter of 2026. The company will need additional funding beyond the next twelve months to reach profitability.

Management Comments

• Management's expectations with respect to its ability to fund current planned operations is based on estimates that are subject to risks and uncertainties.
• If actual results are different from management's estimates, the Company may need to seek additional strategic or financing opportunities sooner than would otherwise be expected.
• There is no guarantee that any of these strategic or financing opportunities will be executed or executed on favorable terms, and some could be dilutive to existing stockholders.
• If the Company is unable to obtain additional funding on a timely basis, it may be forced to significantly curtail, delay, or discontinue one or more of its planned research and development programs or be unable to expand its operations or otherwise prepare for the potential regulatory approval and commercialization of its product candidates, assuming positive data.
• We believe that our claims are meritorious in the binding arbitration proceeding against 3D Medicines.

Industry Context

SELLAS Life Sciences operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically focusing on novel therapeutics for cancer. The positive Phase 2a results for SLS009 in relapsed/refractory AML, particularly exceeding historical benchmarks for overall survival and identifying predictive biomarkers like ASXL1 mutations, position the company favorably within the oncology space. The FDA's recommendation to advance SLS009 into a first-line AML therapy study indicates strong potential for this CDK9 inhibitor to address a significant unmet medical need. The ongoing development of GPS, an immunotherapeutic targeting WT1, also aligns with the growing trend of precision oncology and immunotherapy approaches. The company's ability to secure substantial financing through warrant inducements demonstrates investor confidence in its pipeline, a critical factor for clinical-stage biotechs.

Comparison to Industry Standards

• SLS009's median overall survival (mOS) of 8.9 months in AML MR patients and 8.8 months in r/r to venetoclax-based regimens at a 30 mg BIW dose level significantly surpassed the historical benchmark of approximately 2.4 months for similar patient populations, indicating superior efficacy compared to existing or historical treatment outcomes.

Corporate Governance

Legal Proceedings

• A binding arbitration proceeding was commenced on December 20, 2023, against 3D Medicines Inc., administered by the Hong Kong International Arbitration Centre. The arbitration involves the trigger and payment of approximately $13.0 million in milestone payments due to the company under the 3D Medicines Agreement, as well as 3D Medicines' alleged failure to use commercially reasonable best efforts to develop GPS in the 3DMed Territory. The company believes its claims are meritorious.

Stakeholder Impact

• **Shareholders**: Significant dilution from recent capital raises (increased shares outstanding from 73.9M to 125M by Sep 30, 2025, and 142.4M by Nov 11, 2025). However, strengthened liquidity and positive clinical data for SLS009 could lead to future value creation. The ongoing arbitration with 3D Medicines introduces uncertainty regarding potential future licensing revenue.
• **Employees**: Continued stock-based compensation and employee stock purchase plan provide incentives and opportunities for ownership.
• **Patients**: Positive clinical trial results for SLS009 in r/r AML and promising preclinical data for pediatric ALL offer hope for new, more effective treatment options for severe cancer indications.
• **Creditors**: Improved cash position and extended liquidity runway reduce immediate credit risk.

Next Steps

• Final analysis of the REGAL study (GPS in AML) is anticipated once 80 events (deaths) are reached this year.
• Preparation for a randomized 80-patient trial for SLS009 in newly diagnosed, first-line AML patients, with enrollment expected by the first quarter of 2026.
• Continued evaluation of the impact of the 'One Big Beautiful Bill Act of 2025' (OBBBA) on consolidated financial statements.
• Continued evaluation of the impact of ASU No. 2023-09 (Improvements to Income Tax Disclosures) and ASU 2024-03 (Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures) on financial statements.
• Resolution of the binding arbitration proceeding against 3D Medicines regarding milestone payments and development efforts.

Key Dates

Recommendation

The filing presents a compelling case for a 'buy' recommendation, particularly for investors with a higher risk tolerance and long-term horizon in the biotech sector. The significant clinical advancements for SLS009, including meeting all primary endpoints in a Phase 2a AML trial, surpassing historical survival benchmarks, and receiving FDA guidance for a first-line study, are strong indicators of its therapeutic potential and market opportunity. The multiple regulatory designations (ODD, Fast Track, RPD) further underscore the unmet medical need and potential for expedited development. While the company continues to operate at a loss, the substantial capital raises have significantly bolstered its cash position, providing a crucial runway for ongoing and planned clinical programs for at least the next 12 months. The ongoing GPS REGAL study also holds potential. The primary risks remain the inherent uncertainties of clinical development, regulatory approvals, and the outcome of the 3D Medicines arbitration, but the recent positive data and strengthened financial footing suggest a favorable risk-reward profile for growth-oriented investors.

Keywords

SELLAS Life Sciences, SLS, Galinpepimut-S, GPS, SLS009, Tambiciclib, AML, Acute Myeloid Leukemia, CDK9 inhibitor, WT1 antigen, Oncology, Immunotherapy, Clinical trials, Phase 3 REGAL study, Phase 2a AML trial, Orphan Drug Designation, Fast Track Designation, Rare Pediatric Disease Designation, Biopharmaceutical, Cancer therapeutics, ASXL1 mutation, Preclinical data, Capital raise, Warrant inducement, SEC filing, 10-Q